Surface Oncology to Present at Two Upcoming Healthcare Conferences
May 15 2019 - 4:00PM
Surface Oncology (NASDAQ:SURF), a clinical-stage
immuno-oncology company developing next-generation immunotherapies
that target the tumor microenvironment, announced that Jeff Goater,
chief executive officer, will be participating and presenting a
corporate update at the UBS Global Healthcare Conference on
Wednesday, May 22, 2019 at the Grand Hyatt New York in New York
City.
Additionally, Dr. Pamela Holland, PhD, vice
president of cancer biology, will present at the Brisbane
Immunotherapy 2019 Conference. Her presentation, “Targeting
the Adenosine Axis to Treat Cancer” will take place on Friday, May
24, 2019 at the Brisbane Convention Centre, in Brisbane,
Australia.
The presentations will be accessible by visiting
the Investors page of the website at
https://investors.surfaceoncology.com.
About Surface Oncology:
Surface Oncology is an immuno-oncology
company developing next-generation antibody therapies focused on
the tumor microenvironment with lead programs targeting CD73, CD39,
IL-27 and CD47. Surface’s novel cancer immunotherapies are designed
to achieve a clinically meaningful and sustained anti-tumor
response and may be used alone or in combination with other
therapies. The company has a pipeline of six novel immunotherapies
and a strategic collaboration with Novartis focused on
NZV930 (CD73) and potentially one additional undisclosed program.
For more information, please
visit www.surfaceoncology.com.
Contacts: Seth Lewis slewis@surfaceoncology.com
617-665-5031 Krystle Gibbs Ten Bridge Communications
krystle@tenbridgecommunications.com 508-479-6358
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Apr 2023 to Apr 2024